Quest Diagnostics Incorporated reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2016. For the quarter, the company reported net revenues of $1,861 million against $1,849 million a year ago. Operating income was $276 million against $239 million a year ago. Net income attributable to company was $155 million against $188 million a year ago. Diluted earnings per share were $1.09 against $1.29 per share a year ago. Cash provided by operations was $304 million against $272 million a year ago. Capital expenditures were $128 million against $94 million a year ago. Adjusted operating income was $305 million against $288 million a year ago. Adjusted net income attributable to company was $173 million or $1.31 per share against $157 million or $1.19 per share a year ago.

For the year, the company reported net revenues of $7,515 million against $7,493 million a year ago. Operating income was $1,277 million against $1,399 million a year ago. Net income attributable to company was $645 million against $709 million a year ago. Diluted earnings per share were $4.51 against $4.87 per share a year ago. Cash provided by operations was $1,069 million against $821 million a year ago. Capital expenditures were $293 million against $263 million a year ago. Adjusted operating income was $1,230 million against $1,203 million a year ago. Adjusted net income attributable to company was $682 million or $5.15 per share against $640 million or $4.77 per share a year ago.

For the year 2017, the company expects revenues of range between $7.64 billion to $7.72 billion. Reported diluted EPS of range between $4.65 to $4.80 per share. Cash provided by operations of range between $1.1 billion. Capital expenditures of range between $250 million to $300 million.